N/A N=92 Sleep IntervEntion as Symptom Treatment for ADHD
ADHD · Sleep · Adolescents
Primary: Sleep Architecture Objective TST [Total Sleep Time] Pre-test to Post-test — 8.11; 7.94; 8.03; 8.07 hours — p=.17
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=137 Sleep Specialty Consultation: Improving Management of Sleep Disorders
Sleep Disorders
Primary: Provider Adherence to Sleep Specialist Recommendations — 4; 0; 8; 4 participants
Phase 2 N=20 Effect of Background Noise on Sleep Quality
Sleep Onset Insomnia
Primary: Sleep Onset Latency (Mins) — 13; 19 minutes — p=0.011
N/A N=20 Sleep Loss and Mechanisms of Impaired Glucose Metabolism
Primary Insomnia
Primary: Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test — .33; -0.10 %/min, slope of natural log glucose
Phase 4 N=79 Improving Sleep in Nursing Homes
Sleep Deprivation
Primary: Number of Participants Meeting Good Sleep Latency Criteria — 7; 6 participants — p=0.655
N/A N=56 Insomnia Treatment and Problems (the iTAP Study)
Insomnia · Alcohol; Harmful Use
Primary: Insomnia Severity — 6.86; 10.84; 6.58; 9.32 units on scale, Insomnia Severity Index
N/A N=108 Association Between Food/Nutrient Intake and Sleep Quality in Middle Aged and Older Population
Sleep
Primary: Sleep Quality Assessment 1 (GSS) — 3.4; 8.1; 5.2 score on a scale
Phase 3 N=30 Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Parkinson's Disease · Insomnia
Primary: TST — 5.7; 6.0 hours
Phase 4 N=115 Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
Insomnia · Insomnia Chronic
Primary: Treatment Response (Phase 1) — 94 Participants
N/A N=452 Chronic Sleep Deprivation Among the Poor: A Lab-in-the-field Approach
Blood Pressure · Depression
Primary: Sleep Per 24 Hours — 5.61; 5.81; 5.99; 6.23 Hours of sleep/24 hours
N/A N=45 A High Density EEG Comparison of Sleep Patterns in Insomnia
Primary Insomnia
Primary: EEG Power During Sleep — 1.40; 1.17 μV^2/Hz — p=0.2791
N/A N=226 PERSONAL - Sleep In Breast Cancer
Insomnia · Breast Cancer
Primary: Prevalence of Insomnia in a Cohort of Breast Cancer Patients — 170 Participants
N/A N=188 Sleep Without Insomnia or The Use of Chronic Hypnotics
Sleep Initiation and Maintenance Disorders
Primary: Rates of Hypnotic Discontinuation — 64; 52 Participants — p=.039
N/A N=16 Sleep Innovations for Preschoolers With Arthritis (SIPA): Developing and Pilot Testing of a Self-Management Intervention
Juvenile Idiopathic Arthritis
Primary: Feasibility as Assessed by Adherence — 12 Participants
N/A N=39 Sleep Promotion to Improve Diabetes Management in Adolescents With T1D
Diabetes Mellitus, Type 1
Primary: Sleep Quality: Baseline — 4.3; 4.5 score on a scale
N/A N=30 Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses
Nocturia · Hypertension · Sleep Disturbance
Primary: Change in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention — -0.4; 7.3; 3.9 percentage of daytime mean SBP — p=0.65
N/A N=92 Improving Sleep Using Mentored Behavioral and Environmental Restructuring
Insomnia
Primary: Sleep Efficiency (SE) — 76.1 percentage of time in bed
Phase 3 N=127 The Role of Sleep in the Treatment of Cannabis Use Disorders
Drug Addiction
Primary: Sleep Efficiency as Assessed by Percentage of Time Asleep While in Bed — 78; 74 percentage of time asleep while in bed
N/A N=159 Implementing Sleep Interventions for Older Veterans
Insomnia
Primary: Sleep Onset Latency — 21.3; 31.3 Minutes — p=<.001
Phase 4 N=20 Treatment of Insomnia and Glucose Metabolism
Sleep · Insomnia · Insulin Resistance
Primary: Plasma Glucose Level at the 120-minute Time Point of a 75g Oral Glucose Tolerance Test
N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
N/A N=28 The Psychoneuroimmunology of Insomnia
Primary Insomnia
Primary: Positive Antibody Response — 7; 7 participants
N/A N=62 Feasibility, Effectiveness and Efficacy of the PowerSleep Device
Sleep · Sleep Disorders Not Due to A Substance or Known Physiological Condition
Primary: Amount of Slow Wave Activity Detected by the Powersleep Device With and Without Stimulation — 1367.9; 1291.3 microvolts^2 — p=0.061
Phase 3 N=30 Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study
Chronic Insomnia · Primary Insomnia
Primary: Pittsburgh Sleep Quality Index (PSQI) — 7.7; 9.2; 7.0; 8.2 units on a scale
N/A N=199 Sleep Treatment Outcome Predictors: A Pilot Study (STOP-pilot)
Sleep Problem
Primary: Improvement in Insomnia Symptoms Following Online CBT — 2.98; 1.26; 4.69; 2.34 score on a scale
Phase 4 N=5 Improving Sleep Quality in Heart Failure
Sleep Disturbance · Heart Failure
Primary: Sleep Latency — -73.3; 21.9 minutes
N/A N=70 Sleep Treatment Education Program-1 (STEP-1)
Cancer Survivors · Insomnia
Primary: Insomnia Severity Change at 8 Weeks — 7.3; 9.5 Units on a scale
Phase 3 N=126 Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
Insomnia · End Stage Renal Disease
Primary: Insomnia Severity Index (ISI) Short-term — 12.47; 11.97; 13.05 score on a scale — p=0.6761
N/A N=245 The RESTING Insomnia Study: Randomized Controlled Study on Effectiveness of Stepped-Care Sleep Therapy
Insomnia
Primary: Insomnia Severity Index (ISI) — 15.9; 15.4; 12.7; 11.6 score on a scale — p=0.001
N/A N=489 Implementing and Sustaining a Sleep Treatment to Improve Community Mental Part 1: Implementation Health Outcomes
Sleep Disorder · Circadian Dysregulation
Primary: Patient-level Outcome: Patient-Reported Outcomes Measurement Information System - Sleep Disturbance — 63.86; 62.10; 62.81; 62.80 T-score — p=<0.001